Podcasts about Novartis

A.M. Edition for Sept. 1. Apple has a new CEO in the form of John Ternus. WSJ reporter Rolfe Winkler explains how Ternus not only has to follow iconic leader Tim Cook, but also come up with an industry-winning plan for AI. Plus, the SEC asks whether firms promising pre-IPO shares in hot companies actually hold those positions. And President Trump backs the film and TV industry in the hopes that a federal tax credit can save Hollywood. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. The AI Therapist: A WSJ Podcast Series Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Global bond yields are on the rise again, putting rates back at the center of the market conversation. Plus, new trial data from Novartis shows promise for its experimental multiple sclerosis drug. And Pennsylvania Governor Josh Shapiro and Chobani CEO Hamdi Ulukaya join Squawk on the Street following the company's more than $1 billion investment in the state, as Shapiro also discusses his push to rein in the rapid expansion of data centers. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Millions of people live with chronic spontaneous urticaria (CSU) — unpredictable hives and angioedema lasting six weeks or longer with no identifiable trigger. In this episode of the Science of Skin podcast, board-certified dermatologists Dr. Ted Lain and Dr. Michelle Tarbox (Chair, Department of Dermatology, Texas Tech University Health Sciences Center, and host of the Dermosphere podcast) break down what CSU actually is, why it's often misdiagnosed as an allergy, and how it's treated — from first-line antihistamines to omalizumab (Xolair) to the newest option: Rhapsido (remibrutinib), the first oral BTK inhibitor approved for CSU.In this episode, you'll learn:How CSU is diagnosed and why it's classified as a skin disease, not a true allergyThe autoimmune vs. autoallergic subtypes driving chronic hives and angioedemaWhy antihistamine updosing often falls short — and its impact on quality of lifeHow BTK inhibitors like remibrutinib (Rhapsido) work differently than biologics like omalizumabReal patient stories on the toll of chronic hives, misdiagnosis, and finding reliefThis episode is sponsored by Novartis with content independently created by the Science of Skin podcast:Have a question or an idea for a future episode? Email us at inquiry@scienceofskinsummit.com.If you enjoyed this episode, please subscribe, leave a five-star rating, and tell a colleague or friend — word of mouth is how this podcast grows.Topics: chronic spontaneous urticaria, CSU, chronic hives, urticaria treatment, angioedema, BTK inhibitor, remibrutinib, Rhapsido, omalizumab, Xolair, antihistamine-resistant hives, dermatology podcast, autoimmune skin disease

For many young women diagnosed with breast cancer, some of the most important decisions they will ever make happen within days of hearing the words, "You have cancer." While treatment planning begins immediately, patients may also be faced with urgent questions about fertility, future family-building, and preserving options they may not have expected to think about so soon. These conversations often happen during a period of fear, uncertainty, and information overload, leaving many patients feeling overwhelmed and unprepared. In this episode, I'm joined by Dr. Ann Partridge, Vice Chair of Medical Oncology and Chief Clinical Strategy Officer at Dana-Farber Cancer Institute, where she also serves as co-founder and director of the Program for Young Adults with Breast Cancer. A professor at Harvard Medical School, Dr. Partridge is a leading breast oncologist and researcher whose work focuses on improving care and outcomes for young adults with breast cancer. Together, we discuss how breast cancer treatment can affect fertility, why these conversations need to happen early, the options available today, and how patients can make informed decisions while balancing the urgency of cancer treatment with hopes and plans for the future. We also reinforce the hopeful message that having children after breast cancer is often possible - and that preserving future options begins with having the right conversations early. Most importantly, this episode is a reminder that patients deserve information, support, and compassionate guidance when facing life-changing decisions at diagnosis. Resources Mentioned in This Episode For additional information and support, visit the Young and Strong Program at Dana-Farber Cancer Institute, which offers resources and practical guides for young adults with breast cancer, including those who are newly diagnosed, in treatment, or in survivorship, as well as caregivers. The program also provides trusted information about fertility preservation, pregnancy after breast cancer, and breastfeeding. The information shared on Dear Cancer, I'm Beautiful is for educational and informational purposes only and is not intended as medical advice. Always consult your physician or qualified healthcare provider regarding your individual medical care and treatment decisions. The views and opinions expressed by guests are their own and do not necessarily reflect those of Cancer Fashionista. Thank you to Daiichi Sankyo and Novartis for making this episode of the Signature Series possible.

“We don't want to follow the crowd, we want to steer our own path into what we think are the most exciting opportunities for patients.” says Fiona Marshall, President of Biomedical Research at Novartis, joins Bloomberg Intelligence analyst Sam Fazeli to explain the biology-first, modality-second philosophy shaping R&D. Marshall details how Novartis is building radioligand therapy beyond Pluvicto into a broad portfolio across tumor types, while treating delivery as the bottleneck for expanding siRNA beyond the liver. The discussion also explores neuroscience as a growth bet built on earlier diagnosis and intervention, plus why AI productivity depends on embedding data scientists across the organization and training models on Novartis's proprietary data.See omnystudio.com/listener for privacy information.

Technology is opening new possibilities for how multiple sclerosis is monitored, treated and managed. In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Ellen Mowry of Johns Hopkins University and Prof. Letizia Leocani of Vita-Salute San Raffaele University about how innovative medical technologies could transform MS research and clinical care. Together, they explore: How artifical intelligence, wearable devices and digital biomarkers could help monitor MS progression The potential to capture fatigue, cognition, pain, mood, sleep and other symptoms between clinical visits How passive monitoring could provide a more complete picture of everyday life with MS The growing role of virtual rehabilitation, digital therapies and other technologies in bringing care into people's homes Why digital biomarkers require rigorous research and validation before being used in clinical trials From earlier detection of disability progression to more accessible rehabilitation and personalised symptom management, this episode examines both the opportunities and challenges of using technology to improve MS care. --- This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

This January, four big AI × Pharma tools deals were announced at the huge JPM Pharma conference that takes over San Francisco every year. OpenAI-backed Chai Discovery (now worth $4B) was somehow at the heart despite being all of 2 years old. The Science team is proud to bring you the first podcast with cofounder Matt McPartlon and product lead Neil Patil to tell the full story! Editor's note: not to be confused with Chai AI, which was another top pod of ours.Pharma suddenly doing big AI tools dealsFor the non-pharma people, JPM is JP Morgan's annual conference for pharma deal-making that takes over San Francisco for a week in January with hundreds of side events, etc. It's a big thing. Tools deals for pharma are also a big (new) thing: companies that start as AI for Pharma usually end up building their own drug pipelines instead, and the reason is something like this: convincing pharma to use your tool requires proof that your tool works. Proof means good targets, maybe with good clinical validation. If you have that, then it's easier to raise money (with a known, if long path to commercialization) or sell (e.g payment in biobucks) for a specific target than it is to sell to lots of companies on a promise that it will work across their portfolios. The “we'll just partner / build our own drug” optionality proved to be the only good path up until January. What changed? In short, the tools got good enough for drug design teams to trust.Good-enough-to-trust unlocks the ability to scale discovery: get more, better candidates into the lab and animal trials faster. More screening for toxicity, better delivery, etc. This means that what you push to the clinic is more likely to succeed.Tools also unlock new capabilities: mechanisms that are very hard or impossible to develop using lab-based discovery. Designing an antibody that precisely triggers a very specific molecular cascade takes many years of trial and error. Designing bi-specific antibodies (that bind to two different proteins) is similarly difficult. Good design tools can unlock this.RJ: The fact that the quality of the model has jumped means you're enabling things you just plain couldn't do. So it's a step change. It's not an efficiency argument at all, or not so much.Matt: Yeah, exactly. It's kind of interesting, even for us — it took me a while to believe in the thesis, actually. I talked to Josh for months before Chai started... It's like, can I beat a mouse, and then can I do what mice can't do? And then how many levels of interaction can you just keep building on top of that?Everyone playing in the structural / binding space has an angle here, and some will be better than others, but Chai is pointing to a different unlock: getting good molecules right out of the gate (meaning they don't then need as much lab work) means that the iteration time is faster. This turns science into engineering: you can design your systems to reduce friction and hill climb towards one-shotting molecules all the way to the clinic.This, per-se, is not a new thesis: a16z articulated a version of this in 2020. What has changed is that structural models became binding models (how well doesn't this molecule bind to this molecule, aka “binding affinity). Binding models unlock design, which has been steadily improving. Chai's observation is that for engineering problems the best product tends to win, and good technology is a necessary but not sufficient condition. Photoshop for moleculesWith that in mind Chai has invested heavily in partnerships that allow them to learn from their Pharma counterparts. What is kind of cool about working so closely and supporting so many of these partners is we get to really learn about what is the stuff that would be helpful in research. So rather than doing research in a vacuum, based on what would hypothetically be cool, we're able to do informed research based on what our partners have just been organically asking us for help with.— Neil Patil, (Chai product lead)This means better UX, such as a molecule editor that is more like a CAD or graphics design program than a chatbot.Their approach has paid off: since June, Chai has announced three more major deals: Lilly, Novartis, argenx, plus an expansion of their Eli Lily program. This episode is too full of quotable moments for a short blog, so tune in to learn about * Why protein tokens have the highest downstream value of any token * Climbing levels of abstraction as models improve * How Pharma, VC, and research are all just portfolio optimization * How better tech changes the whole portfolio * How relentless focus on simplicity leads to scalePlus much more! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Biotech is living through a paradox: the science has rarely looked more powerful, while the institutions behind it have rarely seemed less trusted. The sector that helped accelerate vaccines, advance cancer treatment, and open new frontiers in brain disease is now facing public skepticism, political pressure on science, and rising competition from countries that see biotech as a strategic national asset. That frustration is being sharpened by affordability concerns, with recent polling finding that nearly six in ten U.S. adults worry about paying for prescription drugs. For an industry built around lifesaving innovation, the challenge is no longer just discovering what comes next; it is proving to the public that those breakthroughs are being developed in patients' best interests.So, how can biotech and pharma restore public trust while continuing to deliver the breakthroughs patients are waiting for?On I Don't Care, host Dr. Kevin Stevenson speaks with Dr. Jeremy Levin, Chairperson of Ovid Therapeutics and author of Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust. Their conversation explores why the public has lost trust in pharma, how pharmacy benefit managers and rebate structures complicate drug pricing, why biotech should be treated as a strategic national asset, and what the industry must do to reconnect with patients.Top insights from the talk…Trust is biotech's central challenge. Dr. Levin argues that the industry's biggest mistake has been losing sight of its covenant with patients. While biotech has delivered transformative medicines, he says the public often sees the industry as profiting from illness rather than partnering in care.Drug pricing is more complex than the sticker price. Dr. Levin points to pharmacy benefit managers, insurers, rebates, and opaque intermediary structures as major drivers of patient frustration, arguing that patients often blame drug companies without seeing how money moves through the system.American biotech faces a strategic test. Dr. Levin warns that if the United States does not protect scientific institutions, support the FDA, and recognize biotech as a national priority, innovation and investment may move elsewhere, including China.Dr. Jeremy Levin is a physician-scientist and biotechnology executive with deep experience leading life sciences companies, boards, strategy, alliances, and business development. He is Chairperson of both Ovid Therapeutics and Opthea, and he previously founded and led Ovid as Chairperson and CEO. He is also Chairman Emeritus of the Biotechnology Innovation Organization, where he helped guide industry leadership across biotechnology policy, innovation, and patient-focused drug development. Earlier in his career, he held senior leadership roles at Teva Pharmaceuticals, Bristol Myers Squibb, and Novartis.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By combining their resources, the new entity is expected to enhance its capabilities in neurological disorders with a robust portfolio of approved drugs. This merger allows the companies to leverage economies of scale, optimize research and development, and expand their market presence, offering promising prospects for advancements in treating CNS-related conditions. In regulatory news, Novartis has secured FDA approval for an expanded indication of Pluvicto (lutetium vipivotide tetraxetan), a radioligand therapy originally approved for PSMA-positive metastatic castration-resistant prostate cancer. This therapy can now be used for metastatic hormone-sensitive prostate cancer, marking a significant step forward in prostate cancer treatment. By targeting prostate-specific membrane antigen (PSMA) with precision, Pluvicto offers the potential for improved patient outcomes and highlights the growing role of radioligand therapies in oncology. Globally, Pharmamar's Zepzelca (lurbinectedin) has been approved in Canada, Qatar, and South Korea as a first-line maintenance therapy for extensive-stage small cell lung cancer. This approval signifies a potential shift in how aggressive cancer types are treated, particularly when combined with PD-L1 inhibitors, opening new avenues for effective combination therapies. Industry partnerships continue to drive innovation, as seen with Fujifilm and Taiho Pharmaceutical's collaboration to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the Aralinq platform. With ADCs becoming increasingly pivotal in targeted cancer therapies due to their precision in delivering cytotoxic drugs to tumor cells, advancements in manufacturing could significantly enhance production capabilities and therapeutic efficacy. Financial dynamics within the industry remain robust. AbbVie has raised its 2026 revenue forecast to $67.6 billion, citing strong performances from its immunology drugs Skyrizi and Rinvoq. These therapies have shown substantial success in treating autoimmune conditions, reflecting their impact on AbbVie's financial health and reinforcing confidence in their commercial viability. On the clinical trial front, Ratio Therapeutics has successfully closed a $70 million Series C funding round to support its radiotherapeutics pipeline and initiate the ATLAS trial. This infusion of funds underscores the continued interest and investment in radiopharmaceuticals with promising applications in oncology. The landscape of mergers and acquisitions remains active as AstraZeneca and Bristol Myers Squibb reportedly engage in early-stage merger discussions. Such a merger could create an oncology giant valued at approximately $400 billion, potentially reshaping competitive dynamics and accelerating innovation across therapeutic areas. Regulatory changes are also underway with HRSA advancing a revised 340B rebate model pilot program despite hospital opposition. The implications for healthcare providers are significant as this could affect operational efficiencies and financial strategies within participating entities. Overall, these developments reflect ongoing trends toward industry consolidation and strategic partnerships that foster innovation in drug manufacturing technologies. Regulatory approvals continue to advance precision medicine through targeted therapies, showcasing the sector's dynamic nature as it addresses unmet medical needs while navigating complex regulatory environments. Meanwhile, Sandoz's settlement of nearly $500 million for antitrust claims in the U.S. highlights ongoing scrutiny of industry competition practices. This settlement signals potential shifts in market dynamics as companies seek to resolve legal challenges while maintaining operational integrity. Cybersecurity has emerged as a critical concern following Amgen's reported breach compromising sensitive patient data. This incident amplifies the need for enhanced data protection measures to safeguard information integral to patient trust and competitive integrity. In leadership news, BioNTech has appointed Guido Oelkers as CEO amid its continued innovation in mRNA technology post-COVID-19. This strategic move underscores BioNTech's commitment to leadership capable of navigating advances in mRNA therapeutics. Lastly, Novo Nordisk faced setbacks with its investigational therapy ziltivekimab failing a phase 3 trial targeting inflammatory pathways for cardiovascular outcomes. Despite such challenges, these high-stakes trials highlight both risks and opportunities inherent in pharmaceutical innovation. As we reflect on these stories, it's clear that scientific advancements, regulatory developments, and strategic business moves continue to shape the trajectory of the pharmaceutical and biotech sectors. These efforts promise significant implications for future drug development and patient care as companies strive to harness breakthroughs while adapting to evolving industry landscapes.Support the show

Läkemedel som i framtiden kan signalera om dess användning - praktiskt för glömska men leder till ökad övervakning. Lyssna på alla avsnitt i Sveriges Radios app. I år har det som kallas smarta piller med en antenn producerats. De kan signalera när de nått fram till magsäcken och ge information om att läkemedlet nåt sitt slutmål. Än så länge har det bara testats i grisar. Av flera så kan det uppfattas som ett sätt att säkra att läkemedel verkligen har inmundigats. Medan andra undrar om det inte finns enklare sätt att få patienter att vilja ta de läkemedel som förskrivs. Å frågan är vad som händer för patienter som redan är rädda för läkemedel.Medverkar gör Peter Hovstadius, medicinsk chef för LIF, de forskande läkemedelsföretagen, Eva Flock, kanslichef för Centrum för bättre läkemedelsanvändning, Läkemedelsverket, Max Herulf, avdeldningschef på E-hälsomyndigheten, Tobias Bäckström, medicinsk chef i Norden för Novartis samt Mikael Sandlund, professor i psykiatri vid Umeå universitet och sakkunig i Statens medicinetiska råd, SMER. Alla hade tidigare deltagit i ett seminarium av SMER under Almedalsveckan i Visby. Programledare Annika ÖstmanAnnika.Ostman@sverigesraido.seProducent Michael BorgertMichael.Borgert@sverigesradio.se

Jennifer Garvey Berger is a leadership coach, developmental psychologist, and the author of several books, including: Unlocking Leadership Mindtraps, Changing on the Job, and Unleash Your Complexity Genius. In 2023, she was shortlisted as one of the top 8 coaches in the world by Thinkers 50. In this conversation, we explore: — Daniel Gilbert's idea that human beings are works in progress that mistakenly think they're finished - and the implications this has for growth and development — The 4 minds: self sovereign, socialized, self authoring, and self transforming - and how to know which stage you are at — What it means to become a ‘complexity genius' — The importance of continuously upgrading our mental models all throughout life - and how best to do this. And more. You can explore Jennifer's work and books at https://www.cultivatingleadership.com. --- Jennifer Garvey Berger believes that leadership is one of the most vital renewable resources in the world. At a time when organisations are often forging the path rather than following the path of others, leadership is about creating the conditions for people to be their most creative, connected, intelligent selves. She is a founding partner and CEO of Cultivating Leadership, a consultancy that serves executives and executive teams in the private, non-profit, and government sectors around the world. Her clients include Google, Microsoft, Novartis, Wikipedia, and Oxfam International. Jennifer designs and teaches leadership programs, coaches senior teams, and supports new ways of thinking about strategy and people with clients facing these dramatic shifts in complexity, volatility, and change in their workplaces and markets. She blends deep theoretical knowledge with a driving quest for practical ways to make leaders' lives better. Jennifer also supports leaders one-on-one as a leadership coach. She supports clients to find their current growing edge and then make choices about how they want to grow, and she teaches coaches around the world transformational and developmental coaching approaches in her Growth Edge Coaching certification series. Jennifer speaks at leadership and coaching conferences, and she offers occasional courses for coaches at universities all over the world like Harvard University, the University of Sydney, and Oxford Brookes University. Jennifer holds a doctorate in adult development from Harvard University, where she studied under and worked with acclaimed developmental psychologist Robert Kegan. She was an Associate Professor at George Mason University before she left the academy on a mission to connect powerful research and the people doing real work in the world. Jennifer is an American by birth, a Kiwi by choice, and finds herself living now in London, far from her beach house on the Tasman Sea. Wherever she might call home, she loves laughing with her two nearly-grown children, rolling on the floor with her dog, and writing about leading, coaching, and living. --- Interview Link: — Jennifer's website - https://www.cultivatingleadership.com

In this episode of the NVus Alien Podcast, Heather Woodward begins a three-part investigation into the mysterious deaths and disappearances of eleven scientists whose work spanned aerospace engineering, plasma physics, astronomy, chemistry, and biomedical research. After spending more than three months researching publicly available information, Heather examines a series of cases that have fueled speculation across the internet while separating documented facts from unanswered questions. Rather than presenting conclusions, this series explores recurring themes, timelines, and scientific fields that appear throughout these cases. Part One focuses on five individuals whose work intersected with organizations including NASA's Jet Propulsion Laboratory (JPL), Caltech, MIT, and Novartis.Become a supporter of this podcast: https://www.spreaker.com/podcast/nvus-alien--4798594/support.

This is At the Table, the Food Allergy Podcast—a show about food, connection, and living with food allergies. Each episode, we pull up a chair to a different table—from date nights to tables abroad—and discuss navigating each moment while still eating safely. Because living with food allergies isn’t just about what you can’t eat; it’s about still having your seat at the table. This show is brought to you in partnership with Genentech and Novartis. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after accidentally eating one or more foods to which you are allergic. While taking XOLAIR you should continue to avoid all foods to which you are allergic. It is not known if XOLAIR is safe and effective in people with food allergy under 1 year of age. XOLAIR should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. What is the most important information I should know about XOLAIR? Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction: wheezing, shortness of breath, cough, chest tightness, or trouble breathing low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom” flushing, itching, hives, or feeling warm swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction. Please see the full Prescribing Information for additional safety information, including Boxed Warning, and Medication Guide by visiting bit.ly/XOLPISee omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

In 2014, Collin Henderson was young, in shape, and had blood pressure in the 150s. Anxiety. Depression. Completely stuck. And no idea why. What broke it open wasn't a book or a seminar. Someone handed him a framework for his mind, the same way athletes get a framework for their body.  Proactive. Repeatable. Trained. That framework became the foundation of everything he teaches today. Collin Henderson is the founder of Master Your Mindset, a mental conditioning coach to Nike, Microsoft, Amazon, and Salesforce, and one of the most practical mindset teachers George has ever had on the show. This conversation is a masterclass in what it actually looks like to train your mind, not just hope it cooperates. What You'll Learn In This Episode: Why mindset is conditioning, not motivation and the difference between the training room and the weight room The 6,000 vs. 70,000 thought problem and why the untrained mind always loses The "What x3" coaching framework to get unstuck fast Why identity is the bullseye and how your words are either coding you to win or fail Collin's 4-minute HA Method daily mental workout The bison vs. cattle framework for navigating hard seasons with people by your side The Oz Method for influence, sales, and human connection What "victory goes to the vulnerable" actually looks like in practice Key Takeaways: ✔️If the mind is untrained, the thought will win. If the mind is trained, the thinker will win. ✔️80% of human thoughts are negative. 95% are recurring. You're not stuck because of circumstances, you're stuck because of cycles. ✔️You never outperform your self-image. Identity is the bullseye. Words are your wand. ✔️Prehab, not rehab. The mind gym is proactive work, not something you do after you're broken. ✔️Gratitude lowers cortisol by nearly 30%. It's not soft. It's science. ✔️The 4-minute HA Method: breathe (1 min), I Have, gratitude, I Am, self-talk, I See, visualization. Borrow the future to build the present. ✔️Fear loves isolation. Nobody should worry or win alone. Do you have bison people? ✔️Asking for help is not weakness. Hiding and trying to do it yourself is. ✔️Victory goes to the vulnerable, because the coward and the warrior both feel fear. The difference is what they do with it. Timestamps & Highlights: [00:03] — 2014: high blood pressure, anxiety, depression, and the framework that broke it open [01:27] — Welcome: George's Yoda for mindset has entered the building [04:20] — Why knowing mindset matters and doing something about it are two completely different things [07:00] — The training room vs. weight room: what mental conditioning actually is [09:16] — 6,000 conscious vs. 70,000 subconscious thoughts — and why the untrained mind loses [13:07] — The "What x3" framework to get clarity when you're stuck [15:55] — Identity is the bullseye: how your words are literally coding your brain to fail or win [18:21] — Living by design vs. default — and your right to be average [28:00] — Designing places for your brain to go before pressure arrives [32:38] — It begins before it begins: the high-performance pre-game [35:01] — Victory goes to the vulnerable — and what the coward and warrior have in common [38:42] — The 4-minute HA Method: breathe, I have, I am, I see [44:00] — Gratitude: the research, the results, and why it's not optional [47:00] — Michael Phelps, decisive self-talk, and the number one driver of confident action [56:23] — The Oz Method book: connect with curiosity, clarify with story, collaborate on solutions [1:03:48] — The three Oz characters and the Scott story: from PIP to president's club in 11 months Connect with Collin Henderson He is the founder of Master Your Mindset, LLC, a two-sport Division I athlete, former top-ranked medical sales professional, and mental conditioning coach whose clients include Nike, Microsoft, Salesforce, Amazon, Novartis, #1 NBA draft picks, and Heisman finalists.  He's authored seven books and hosts the Master Your Mindset podcast. His new book, The Oz Method, releases June 20th. Website: thecollinhenderson.com   Instagram: instagram.com/collinhenderson   YouTube: https://www.youtube.com/@collinhenderson6749 Quiet Mind Course: thecollinhenderson.com/quietmindcourse   The Oz Method: Available for pre-order on Amazon Your Challenge This Week: Pick one thing from this episode. One. Give it 90 days. Then connect with Collin, follow him on Instagram, try the Quiet Mind Course, or grab The Oz Method on Amazon. Follow George: @itsgeorgebryant Work with George:The Alliance — Community for entrepreneurs training their minds alongside their business.  1:1 Coaching — Limited spots. Apply at mindofgeorge.com/coaching-consulting/   Live Retreats — In-person experiences where mindset and strategy meet. Follow for dates.

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of significant breakthroughs and strategic moves reshaping the industry landscape. Repligen Corporation's recent decision to acquire BioLife Solutions for $1.5 billion marks a pivotal moment in the cell therapy sector. BioLife Solutions' expertise in cryopreservation media is integral to maintaining cell viability during storage and transport—an essential factor for the success of cell therapies in oncology and regenerative medicine. This acquisition ensures Repligen a stable supply chain to support the burgeoning demand for advanced therapeutic options, potentially enhancing patient outcomes through more reliable treatments. Meanwhile, Novartis is expanding its reach in South Korea with a $95 million investment aimed at enhancing its radioligand therapy supply chain. Radioligand therapy represents a groundbreaking approach in oncology, utilizing targeted radioactive particles to specifically attack cancer cells while sparing healthy tissue. This strategic investment underscores Novartis's commitment to ensuring a robust infrastructure for delivering innovative cancer treatments. On the clinical front, Crystalys Therapeutics has made waves by securing $130 million in Series B funding, propelling their gout treatment, Dotinurad, into Phase 3 trials. This drug targets uric acid levels, addressing a significant unmet need in gout management. The progression into late-stage trials reflects confidence in Dotinurad's potential to provide effective relief for patients suffering from this painful condition. Regulatory advancements are also making headlines with the UK's MHRA granting approval to Chiesi's Clenil Modulite with a low-carbon propellant for asthma maintenance treatment. This move signifies a crucial step towards more sustainable pharmaceutical practices without compromising efficacy—setting a potential benchmark for future respiratory treatments that incorporate eco-friendly technologies. In business development news, Ashlins Pharmaceuticals and Lee's Pharmaceutical have struck a $31 million licensing deal for interferon alpha-2b outside China, focusing on rare diseases. Similarly, Jupiter Neurosciences' acquisition of MDMA asset ALA-002 from Pharmala Biotech illustrates ongoing interest in small molecule therapeutics for neurological conditions. Royalty Pharma's significant $425 million payment to Neurimmune highlights strategic investments in cardiovascular therapies through royalty financing, underscoring confidence in advancing novel treatments. Concurrently, Dimension has raised an impressive $800 million for an AI-driven biotech drug discovery fund. The integration of AI promises accelerated drug development timelines and enhanced precision in identifying viable candidates. However, not every development is favorable. Celldex Therapeutics faced a setback with their Phase 2 trial failure for barzolvolimab in prurigo nodularis patients. Such challenges highlight the inherent risks associated with innovative drug development. Turning our attention to another scientific milestone, Arrowhead Pharmaceuticals has reported promising Phase 3 data on its triglyceride-lowering drug, Plozasiran. With analysts praising its "best-in-class profile," Arrowhead aims for FDA approval by year-end, setting up potential competition with Ionis Pharmaceuticals' Tryngolza. These advancements underscore significant progress in targeting specific lipid disorders and the promise of novel therapies to improve cardiovascular health. Corporate strategies are also evolving as seen with Sanofi undergoing executive restructuring under new leadership by CEO Belen Garijo. This reflects broader industry trends where leadership shifts align corporate strategies with market demands and scientific opportunities. Legal developments have not gone unnoticed either. Amgen's $74 million settlement over allegations of concealing a substantial tax bill highlights ongoing scrutiny over corporate governance within the sector. Meanwhile, industry giants are rallying around regulatory defenses, as evidenced by biopharma companies supporting the FDA amidst legal challenges concerning mifepristone—a move emphasizing the industry's vested interest in maintaining access to drugs based on scientific merit. From a technological perspective, companies are increasingly adopting connected trial technologies to streamline processes such as consent and reporting—advancements crucial for reducing patient burden and accelerating drug development timelines. In conclusion, these developments portray an industry at the forefront of scientific innovation while navigating complex regulatory environments and ethical considerations. As firms continue exploring novel treatment avenues and leveraging technological advancements like AI, they position themselves for transformative impacts on patient care and global health outcomes. We look forward to keeping you updated on these exciting trends shaping the future of pharma and biotech industries.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partnership is set to harness artificial intelligence and machine learning technologies to revolutionize drug discovery and development. By enhancing data analysis and predictive modeling, this collaboration may lead to more efficient identification and validation of drug targets, reflecting a growing industry trend towards leveraging AI to streamline R&D processes. In infectious diseases, Gilead Sciences and Merck & Co. have reported promising phase 3 clinical trial results concerning their combination therapy for HIV treatment. This regimen, combining islatravir and lenacapavir, could become the first weekly oral medication for HIV, offering a significant improvement over daily treatments. Such developments not only promise enhanced patient adherence but also mark a pivotal step forward in long-term HIV management by potentially increasing quality of life for patients. Oncology diagnostics are also seeing significant strides as Tempus AI plans to acquire Personal Genome Diagnostics for $1.5 billion. This acquisition is poised to bolster Tempus's portfolio in cancer minimal residual disease diagnostics. The integration of capabilities from Personal Genome Diagnostics is expected to enhance precision oncology efforts, providing more comprehensive data for personalized cancer treatment plans. Regulatory updates bring more promising news with Takeda's dengue vaccine, Qdenga, securing approval in India. This live-attenuated vaccine targets all four serotypes of the dengue virus, representing a major advancement in regions burdened by dengue fever. Similarly, JCR Pharmaceuticals has received marketing authorization in the UAE for Izcargo, an enzyme replacement therapy that penetrates the blood-brain barrier to treat Hunter syndrome, showcasing innovations in treating rare genetic disorders. Strategic partnerships continue to be a focal point in industry growth. Menarini Asia-Pacific has joined forces with Pharmacosmos to commercialize Cosela across Asia-Pacific regions. Additionally, Halozyme Therapeutics has partnered with Incyte on subcutaneous formulations of a monoclonal antibody using their proprietary Enhaze technology, highlighting advancements in drug delivery systems. Financially, Novartis has shown resilience by returning to sales growth driven by products like Kisqali and Kesimpta amidst generic competition challenges. Meanwhile, Axiom Biosciences is gearing up for an IPO in Hong Kong, indicating a growing interest in stem cell therapies for neurological and rare diseases. Yet not all news has been positive. Novartis has discontinued its phase 2 radioligand therapy targeting gastrin-releasing peptide receptors due to underwhelming results in solid tumors. Agios Pharmaceuticals has similarly halted development of its pyruvate kinase activator for sickle cell disease following unsatisfactory phase 2 data. Legal battles continue as well, with Novo Nordisk suing Eli Lilly over GLP-1 agonists efficacy claims and Moderna locked in patent disputes with CureVac over COVID vaccine technologies. These stories reflect dynamic shifts emphasizing innovation through AI collaborations and novel therapeutic developments in HIV and oncology treatments. They also highlight strategic acquisitions enhancing diagnostic capabilities while revealing challenges such as competitive pressures and regulatory hurdles that companies must navigate. Turning our attention back to scientific breakthroughs, Jennifer Doudna's venture into AI-powered protein design underscores how artificial intelligence continues transforming biotechnology. Her exploration highlights AI's potential to accelerate drug discovery by enabling more precise targeting of disease-related proteins. Additionally, recent successes in personalized medicine include the establishment of a new center dedicated to genetic therapies. Spearheaded by leading scientists, this initiative aims at developing tailored treatments based on individual genetic profiles—advancing precision medicine and reducing adverse effects. In conclusion, these developments illustrate a vibrant landscape where scientific breakthroughs intersect with strategic business maneuvers. As companies navigate these complex waters—balancing innovation with regulatory scrutiny—they continue pushing boundaries that promise improved patient outcomes worldwide while reshaping future healthcare landscapes.Support the show

Thirtieth birthdays are among the most reflective celebrations that we have. Born out of one of the largest corporate mergers in history, Novartis was founded in 1996 and celebrated its 30th anniversary this year. As such, the Swiss pharma giant is reflecting on its corporate branding down to the color palette as it eyes a future where its R&D operations lead to new drugs on the market targeting a host of disease states and medical conditions. In order to articulate its mission and underscore how it has evolved from a marketing perspective, Novartis is taking a look back before it sets its eyes on the future. This week's episode features reporter Bella Czajkowski in conversation with Novartis' chief corporate affairs officer Michelle Weese. The pair discuss the history of Novartis, how it is recognizing its 30 years in business and what we can expect from the drugmaker as it relates to marketing in the months and years ahead. And for our Trends segment, executive editor Jack O'Brien is joined by editor-at-large Steve Madden and pharma editor Lecia Bushak to talk through the FDA's proposed de facto pharma ad ban now that the dust has settled — at least a little bit.  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly's AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.  

Plus: Oil tops $90 a barrel as Middle East conflict continues. And shares of Utz Brands soar after the snack-food maker agrees to go private. Imani Moise hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novartis CEO Vas Narasimhan joins to break down the company's latest earnings report as they return to sales growth. Then, we bring you comments from President Trump as he meets with the President of Lebanon at the White House. Plus, we break down the details of Alphabet's three new Gemini models it released ahead of earnings tomorrow. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New UK Prime Minister Andy Burnham pledges immediate action on the cost of living: scrapping VAT from electricity bills. That, after announcing John Healey as his surprise pick for Chancellor. Elsewhere, Yemen's Houthis impose a naval embargo on Saudi Arabia, while President Trump warns Iran "will pay" for the deaths of US soldiers. And Novartis reaffirms its guidance after beating on the top and bottom lines, with second quarter net sales coming in at almost 14-and-a-half billion dollars.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Program discontinuation is usually the fight presidents avoid. Fairleigh Dickinson University put a significant slate of program discontinuations and consolidations to a faculty referendum, and roughly 88 percent of the faculty endorsed it. The vote reflects a larger redefinition underway at FDU: a shift from the four-year degree to a university built around lifelong learning. In this episode of the Changing Higher Ed® podcast, Dr. Drumm McNaughton speaks with Michael Avaltroni, President of Fairleigh Dickinson University and the first FDU graduate to hold the office, about the four-P framework guiding that redefinition: programs, people, partnerships, and place. Avaltroni explains how FDU is specializing in health, health-adjacent, and professionally focused programs rather than trying to be everything to everyone; designing for five generations of learners on one campus; delivering degrees inside corporations such as Merck, Novartis, Fiserv, and Barclays; and reimagining its campuses as intergenerational "impact cities" that place retirement living alongside student housing. This conversation is especially relevant for presidents, provosts, and board members weighing program portfolio decisions, partnership strategies, and how to pursue radical change without losing faculty and community trust. Topics Covered Why the fundamental model higher education was built for is gone, and the optimistic "but" that follows The four Ps of the university of the future: programs, people, partnerships, and place Winning faculty endorsement of program cuts through a data-driven shared governance process Serving five generations of learners concurrently, from pre-college pathways to retirement Corporate classrooms, advisory councils, executives in residence, and a learn-while-you-earn platform with health systems Humanics: preparing a healthcare workforce that is technologically literate, data literate, and human literate Real-World Examples Discussed A faculty referendum endorsing a significant slate of program discontinuations by roughly 88 percent On-site MBA and leadership programs where practitioners, including a VP of HR, team-teach with FDU faculty Plans to add university-based retirement living alongside student housing on FDU's two New Jersey campuses Three Key Takeaways for Higher Education Leadership Know who you are. Be the institution you are called to be, serving the students you are called to serve, not a copy of anywhere else. Rethink what higher education can be. The time-driven, hours-logged degree has run its course; the strategic question is how to deliver true lifelong learning, at its fullest a subscription-based model for life. Be bold. Institutions that nibble around the edges risk obsolescence; take a big swing and adjust course, and bring everybody along. This episode offers a working view of what redefining a university around lifelong learning actually requires: a clear identity, a disciplined portfolio, partners who carry what the institution should not, and governance strong enough to carry hard decisions. Read the transcript: https://changinghighered.com/fairleigh-dickinson-lifelong-learning-ecosystem/ #HigherEducation #HigherEducationPodcast #LifelongLearning

En Capital Intereconomía seguimos la apertura del Ibex 35 y del resto de las bolsas europeas en una jornada de tendencia mixta, marcada por la evolución de los resultados empresariales, la incertidumbre geopolítica y el comportamiento de las grandes compañías internacionales. En el análisis de mercados hablamos con Pablo García, director de Divacons-AlphaValue, para valorar las principales referencias que condicionan la sesión bursátil. Analizamos el impacto de la situación geopolítica sobre los mercados, el comportamiento de la renta variable europea y las perspectivas para los distintos sectores en un contexto en el que los inversores continúan pendientes de la evolución de los tipos de interés y de la temporada de resultados. También ponemos el foco en Novartis, cuyos beneficios superan las previsiones del mercado, confirmando la vuelta al crecimiento de la farmacéutica suiza. Además, analizamos la evolución de SpaceX, que desciende hasta el octavo puesto entre las compañías más valiosas, en un contexto de creciente competencia dentro del sector tecnológico y aeroespacial. Terminamos con el Consultorio de Bolsa junto a Javier Alfayate, gestor de fondos, que responde a las consultas de los oyentes y analiza desde el punto de vista técnico los principales valores nacionales e internacionales, identificando tendencias, niveles clave y oportunidades de inversión.

Die Halbjahreszahlen von Novartis fallen besser aus als erwartet: Der Umsatz steigt leicht, der Reingewinn sinkt. Im zweiten Halbjahr wird Novartis drei grosse Zulassungsstudien vorstellen. Stefan Schneider, Pharma-Analyst bei Vontobel, rechnet für die Aktie mit einem volatileren zweiten Halbjahr. SMI: +0.3%

Araceli de Frutos, asesora del fondo Alhaja Inversiones, pone el foco sobre Airbus, Siemens, Novartis, Swatch y Volkwagen.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

Novartis CMO Gail Horwood joins Janet Balis, Managing Director & Senior Partner at BCG, to explore how one of the world's largest pharmaceutical companies is redefining healthcare marketing.Fresh from winning two Cannes Lions, Gail shares how Novartis is proving that creativity can thrive even in one of the most heavily regulated industries. From partnering with the NFL for a Super Bowl campaign to convincing stakeholders to embrace bolder ideas, we discuss what it takes to create work that stands out while navigating complex regulations.The conversation also explores how AI is reshaping both creativity and business transformation, where marketers should focus their efforts, and why the biggest opportunity for AI isn't just efficiency, but unlocking growth.This episode has been produced in partnership with BCG. Browse their CMO Report here:https://www.bcg.com/publications/2026/making-the-agentic-marketing-transformation-a-realityTimestamps00:00 - Start00:49 - Jon's full circle moment with Norvatis01:39 - Novartis' journey to two Cannes Lions02:54 - Why more people need to walk the work04:05 - Creating surprising advertising in a heavily regulated category09:03 - Partnering with the NFL for a Super Bowl campaign10:24 - How to get your company to embrace risky work16:01 - How to get stakeholders outside of marketing onboard19:35 - The reaction to the ads after Super Bowl21:56 - How AI is being used in the service of creativity27:04 - How Novartis are using AI for creativity30:27 - How Novartis are rethinking their marketing with AI32:46 - Where AI is going to be used outside of marketing35:03 - AI for efficiency vs growth37:16 - How to deliver leadership change in the age of AI40:22 - The boring things AI will solve42:53 - What makes Gail such a good CMO44:25 - The worst way to evaluate your career success45:57 - The best advice Gail has ever received

HEADLINES:• This very special episode is sponsored by Novartis• Dubai Police Recovered AED 10 Million Just 10 Minutes After A Robbery• Scammers Are Selling Fake Cheap Car Insurance On Social Media• Indian Passport Services In UAE Face More Delays After A New Court Ruling• Tributes Poured In As HH Sheikh Mohammed Marked His 77th Birthday• Oncologist Dr. Saeed Rafii Explains  Why Women In The UAE Being Diagnosed With Breast Cancer Younger

For many women, one of the most challenging parts of life after breast cancer isn't something they expected at all: menopause. Whether caused by chemotherapy, ovarian suppression, surgery, or hormone-blocking therapies, treatment-induced menopause can arrive suddenly and bring significant physical and emotional changes that impact nearly every aspect of daily life. Yet many survivors say they were never fully prepared for what comes next. In this conversation, Dr. Corinne Menn shares both her professional expertise as an OB/GYN and menopause specialist and her personal experience as a breast cancer survivor who has faced many of these challenges herself. Together, we discuss why menopause after breast cancer can feel so different from natural menopause, the symptoms that often catch us off guard, the confusion surrounding hormones after cancer, and how survivors can advocate for the support and quality-of-life care they deserve. This episode of the Dear Cancer, I'm Beautiful Signature Series was made possible by Novartis and Daiichi Sankyo.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show

Do you have an Apple watch? Fitbit? Oura ring? Woop? Wearables have taken over in the past decade with claims that by constantly monitoring our heart rate, sleep, respiration, and activity, they can provide health data that can change your life. But is that really possible? Or even plausible? Marco Benitez, former professional athlete, and the Founder and CEO of ROOK joins us on the Living Well series today to talk all things wearables. He sees tremendous potential with how the data these tools compile can be utilized across all aspects of our lives, including in our cars (!), to change our behavior. But he acknowledges there's a catch. Many of these companies use the data collected not for YOUR benefit, but for theirs, and real change, well, there's no magic bullet. It's hard, takes time, and is all on you. Raised in Mexico with an insatiable curiosity and entrepreneurial spirit, Marco Benitez built his career at the intersection of health, technology, and sports science. Starting as a Tae Kwon Do champion, Marco's discipline and resilience guided him into biomedical engineering, then into high-stakes roles in pharmaceutical giants like Roche and Novartis. Here, he witnessed the transformative power of data in healthcare—and saw a profound opportunity to make health metrics more accessible and actionable. Determined to improve health management and bridge the gap between raw data and real impact, Marco co-founded ROOK.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

— How many times have we remained silent when something important needed to be said? How often have we hidden our thoughts, emotions, needs, or truths out of fear of judgment, rejection, conflict, or simply not being heard? Many of us learn, often from an early age, that staying quiet is safer than speaking up. Over time, those patterns can become so familiar that we hardly notice them. We silence our ideas, our creativity, our boundaries, our needs, and sometimes even our authentic selves. But what is the cost of that silence? Today, we'll explore how silence shapes our lives, relationships, workplaces, and communities, and how we can begin to recognize and unlearn the unconscious patterns that keep us from fully expressing who we are. We'll discuss the courage required to speak our truth, the importance of creating spaces where all voices are welcomed, and how authentic self-expression can lead to greater connection, belonging, personal growth, and well-being. At its heart, this conversation is an invitation to reclaim our voice—not to speak louder, but to speak more honestly, more intentionally, and more fully from who we truly are. Valeria interviews Elaine Lin Hering  — She is the author of  "Unlearning Silence: How to Speak Your Mind, Unleash Talent, and Live More Fully." Elaine Lin Hering is a speaker, facilitator, and former Lecturer on Law at Harvard Law School. She works with organizations and individuals to build skills in communication, collaboration, and conflict management. She has worked on six continents and facilitated executive education at Harvard, Dartmouth, Tufts, UC Berkeley, and UCLA. She has served as the Advanced Training Director for the Harvard Mediation Program and a Managing Partner for a global leadership development firm. She has worked with coal miners at BHP Billiton, micro-finance organizers in East Africa, mental health professionals in China, and senior leadership at the US Department of Commerce. Her clients include American Express, Chevron, Google, Nike, Novartis, PayPal, Pixar, and the Red Cross. She was named a Thinkers50 global management thinker on the rise.  To learn more about Elaine Lin Hering and her work, please visit: https://elainelinhering.com/

What happens when the worst moment of your health journey becomes the foundation of your life's purpose?For Anthony Masiello, it started with a letter that told him his body was a bad bet. It ended with an organization helping thousands of people transform their health.In this episode of NHA Today, Dr. Stephan Esser sits down with Anthony Masiello, founder of Lifestyle Telemedicine, former NIH and Novartis healthcare tech executive, and a man who lost 160 pounds over 20 months through lifestyle medicine alone, for one of the most inspiring personal transformation conversations the show has had.Anthony's story is remarkable not just for the weight he lost but for who he became on the other side. From introvert to extrovert. From fear-driven to purpose-driven. From a data scientist who helped build systems that managed disease to a founder whose organization is helping thousands of people escape it altogether.In this conversation you will learn:The moment a life insurance denial became the turning point that saved his lifeHow he switched from trying to lose weight to trying to get health and why that changed everythingHow he lost 35 pounds in his first 8 weeks and 160 pounds over 20 monthsWhat G-BOMBS are and how they became the foundation of his recoveryHow his doctor took him off blood pressure medication before he finished losing the weightWhat it feels like to break through limitations you had accepted as permanentHow health transformed his confidence, his identity, and his sense of purposeWhy he stopped comparing himself to others and only compares himself to his worstWhat Lifestyle Telemedicine does and how it is making lifestyle medicine accessibleWhy every time someone searches for how to get healthy they are casting a vote for change────────────────────────────────────────ABOUT ANTHONY MASIELLO────────────────────────────────────────Anthony Masiello is the founder of Lifestyle Telemedicine, a healthcare organization making lifestyle medicine accessible nationwide through telemedicine. A former NIH human genome project researcher and Novartis Pharmaceuticals technology executive, Anthony lost 160 pounds through lifestyle medicine in 2006 after being denied a life insurance policy at 33. He has since run marathons, hiked mountains, and built an organization dedicated to helping others do the same.────────────────────────────────────────LINKS AND RESOURCES────────────────────────────────────────Full episode and show notes: NHA Today on YouTubeSubscribeLifestyle Telemedicine: https://lifestyletelemedicine.comLifestyle Telemedicine on InstagramAnthony Masiello on LinkedInFollow Dr. Esser on Instagram

Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury's analysts discuss how the deal fits with the Swiss pharma's cancer toolkit.The analysts then discuss MHRA CEO Lawrence Tallon's Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson's atlases reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress' probe of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660033#ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech00:01 - Sponsor Message: CBRE01:15 - Novartis Buying Myricx08:01 - U.K. Regulation14:44 - DeGette & FDA Reform21:51 - Parkinson's Atlas Insights29:39 - China Trials ProbeTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Broadcom steigt dank neuem Apple-Deal. Microsofts Xbox-Sparte struggelt. TeraWulf mit 20-Mrd.-Deal mit Anthropic. EasyJet wird übernommen. Novartis, Lockheed und Thales kaufen zu. TKMS bekommt Kanada-U-Boot-Auftrag. Walmart (WKN: 860853) bildet jetzt eigene Optiker aus und baut mit OnePay eine Finanz-App mit 6 Mio. Nutzern. Reichen diese smarten Wetten, um das hohe KGV zu rechtfertigen? Pleite-Griechen war einmal. Die Börse in Athen schlägt den DAX. 2027 kommt Griechenland zurück in den MSCI World. Kri-Kri Milk (WKN: A1W3NH), Karelia Tobacco (WKN: A2PW6U) und Lamda Development (WKN: 691513) zeigen, was abseits der Banken geht. Diesen Podcast vom 07.07.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

$163,700 in 4 Months: The Fastest Way to Break Into Pharmaceutical SalesI was a professor who taught thousands of students. I noticed something: formal education doesn't guarantee a high-paying job.That's why I created Medical Sales U.Our system gets results:✓ Self-paced course✓ Online virtual coaching✓ Personal coaching from me✓ Community accountabilityLast month, our members landed offers at: Novartis, Eli Lilly, Novo Nordisk, Thermo Fisher, BaxterAverage: $163,700 compensation in under 4 months.THE COMPARISONMBA Path: $100K+ investment | 2 years | 23% unemploymentMedical Sales U: $4,997 investment | Employed under 4 months | Members landing at Fortune 500sYou could spend $100K on an MBA with no job guarantee. Or invest $4,997 in a system designed to get you hired.Apply: medicalsalesu.com#MedicalSales #PharmaJobs #CareerChange

Join Kortney and Dr. Payel Gupta as they unpack chronic spontaneous urticaria. Together, they define what hives actually are, explain how CSU is different from an allergic reaction and other types of hives, and walk through what is happening under your skin to cause all that itching. This episode was originally published June 6, 2024. We re-released it on June 25, 2026 with a new intro as the perfect foundation before our episode on the new chronic urticaria guidelines. Do you get hives and have no idea why? Then this episode is for you. What we cover in this episode about chronic hives: What hives really are. Urticaria is the medical word for hives, and the two signs are that it itches and it comes and goes. CSU versus other hives. How CSU differs from inducible hives (CINDU) and from an allergic reaction. Histamine and the itch. Why histamine drives the swelling and itch, and why scratching feels so good. What makes hives flare. CSU has no true trigger, but stress and other culprits can set off your mast cells. The Itch Podcast Hives Episodes Explore our full catalog of hives episodes Diagnosis and the basics Ep. 76 Diagnosing Chronic Spontaneous Urticaria Ep. 128 Is Chronic Spontaneous Urticaria an Autoimmune Disease? Ep. 90 Challenges in Diagnosis and Treatment of Chronic Urticaria in Skin of Color Treatment Ep. 78 Chronic Spontaneous Urticaria Treatments Ep. 131 What Is a BTK Inhibitor? Ep. 147 The REMIX Trial: Remibrutinib for Chronic Hives   Ep. 116 Why Fexofenadine Is Considered a Truly Non-Sedating Antihistamine Living with chronic hives Ep. 148 How Do You Know Your Chronic Hives Are Under Control?  Ep. 122 Mortality in adult patients with chronic spontaneous urticaria: A real-world cohort study  Ep. 80 Chronic Spontaneous Urticaria Myths and Misconceptions Ep. 79 Living with Chronic Spontaneous Urticaria: A patient story Ep. 91 A Patient's Experience with Chronic Urticaria and Skin of Color Ep. 107 Hives in the Latinx Community ______ This podcast is made in partnership with Allergy and Asthma Network.  We thank Novartis for originally sponsoring this episode. This podcast is for informational purposes only and does not substitute professional medical advice. Any mention of brands is also informational and not an endorsement. Always consult with your healthcare provider for any medical questions or concerns.  

Most UX professionals spend years trying to be good at everything. Eric Shumake, founder of HXR Labs, spent 20 years getting really good at one thing and it kept opening doors he didn't expect.Eric is a principal UX researcher and a well-known voice in healthcare UX. His career has taken him through companies like Pfizer, Johnson & Johnson, Novartis, Myriad Genetics, and AliveCor.He also teaches, including a popular course on Maven on breaking into healthcare UX, and has been exploring how AI can meaningfully (and responsibly) augment research without replacing the judgment that makes research trustworthy.In this episode, Eric and Sarah cover a lot of ground: how specializing almost always beats generalizing, what surprises people when they try to bring standard UX practices into clinical environments, why Eric thinks of every role as a gig, and what he'd prioritize if he were managing someone's job search like a product.Topics Discussed✅ Why specializing beats generalizing and how to niche down even when it feels risky✅ How transferable skills work in practice: why experience in one highly regulated industry (like finance) can open doors in another (like healthcare) ✅ The biggest blind spot people bring into healthcare UX✅ Why "recommendations are where insights go to die" and how to tie research to decisions and numbers so stakeholders actually act on it✅ Treating every role as a gig and why that mindset is more practical than it sounds in today's job market✅ Why posting consistently on LinkedIn is one of the highest-leverage things a UX professional can do in a job search right now✅ Where AI genuinely helps in UX research (desk research, competitive analysis, automating the time-consuming parts) and where to draw a hard line✅ What neurodivergence in the workplace looks like from the insideduring a job searchLinks & Resources

Episode 432 of The VentureFizz Podcast features Johannes Galatsanos, CEO & Co-Founder of Diffraqtion. I'm incredibly lucky to host this show because the guests I interview are truly out to rewrite the rules of what's possible. Johannes is a perfect example. He brings over 15 years of deep expertise across AI, quantum tech, and operations across a career that includes lots of deep research in academia to executing massive, corporate AI initiatives at global giants like Novartis. So, what does someone with that background do to push the absolute limits of technology? How about building a space company that is creating the world's first quantum camera to help satellites and machines see further and think faster? By blending quantum photonics with cutting-edge AI edge-computing, Diffraqtion's technology enables satellites and telescopes to bypass traditional lens constraints entirely—delivering 20 times higher resolution and 1,000 times faster processing speed, all at a fraction of the cost. As you'll hear from this interview, there are a countless number of use cases and industries that are perfect for Diffraqtion's technology, which puts them in an ideal spot to build a massive anchor tech company in the Boston startup scene. Chapters: 0:00 Intro 02:37 What is Quantum Computing? 11:40 Johannes' Childhood in Greece and Early Interests 14:52 Transition from Academia to Industry 20:46 Introduction to Diffraction and the Quantum Camera 25:03 Quantum Camera Applications in Space Domain Awareness and Earth Imaging 27:26 Commercializing the technology 28:48 Manufacturing Challenges and Building the Quantum Camera 33:56 Building in Public and Strategic Networking 39:38 Their Innovative Rolling Funding Strategy and Capital Efficiency 45:50 Perfecting their Investor Pitch 49:08 Why Boston for Space Tech Innovation? 53:26 Excitement About Space Industry and Artemis Missions 55:43 Closing Remarks

This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

Turn Setbacks Into Wins With Neutral Thinking   Success does not protect you from feeling stuck. In fact, for many high achievers, the pressure to keep performing can bury the deeper questions that actually matter. This conversation with Joshua Lifrak is about what happens when the old way of thinking stops working and you need a more honest framework for resilience, growth, and living with intention. Joshua knows this terrain from both sides. He grew up around financial scarcity, built a career in elite performance, and lived through bankruptcy before rebuilding. Along the way, he worked with top athletes and organizations, including the Chicago Cubs during their 2016 World Series run, and built a framework for performing under pressure that now serves business leaders as well.   In This Episode: How childhood scarcity shaped Joshua's early relationship with money Why bankruptcy became a turning point instead of an ending What elite athletes understand about mental preparation that most executives do not The power of neutral thinking in high-pressure moments Why knowledge without action changes nothing How to stop living by default and start living by design What "Mile Zero" means for your next chapter   Key Insights: The story you attach to a setback often creates more damage than the setback itself. Neutral thinking creates space for better decisions. Real performance is built before the pressure moment arrives. Growth comes from repetition, not occasional inspiration. The past only controls the future if you keep giving it that power.   Money Learnings from Joshua: He grew up with a scarcity-based relationship to money and remembers what it felt like when finances were tight at home. School did not teach him much about money, and he says he did not truly begin to understand how money could work for you until later in life. He credits his wife, Karen, with helping shape a more thoughtful financial approach through long-term planning, investing, and thinking differently about how to use money to create freedom and better choices.   Why This Conversation Matters: It speaks directly to entrepreneurs and high achievers who know what pressure feels like. Success does not eliminate setbacks, self-doubt, or emotional overreaction. In many cases, it raises the stakes. Joshua brings a rare perspective because he connects personal financial struggle, elite athletic performance, and business leadership into one practical framework. For anyone building a company, leading a team, or trying to grow through a difficult season, this episode is a reminder that better results often begin with better thinking. This is what makes the conversation so relevant for entrepreneurs and high achievers. Success does not remove pressure. It often amplifies it. And when pressure rises, the real question is whether you will react emotionally or respond with intention. Joshua's concept of neutral thinking offers a grounded way forward.   About Joshua Lifrak: Joshua Lifrak, M.S., author of WIN TODAY, is Director of Performance and Coaching at Limitless Minds, a mental performance consultancy, delivering keynotes and advising individuals, small businesses, and top multinationals including McDonalds, Novartis, Pfizer, KPMG, and Amazon. He started his career as a mental conditioning consultant with IMG Academy, working with MLB players, NBA and NFL draft picks, the US Soccer U-17 Men's National Team and many elite college programs. He then joined the Chicago Cubs as director of their mental skills program. His work there culminated in the Cubs' 2016 World Series victory. After his stint with the Cubs, he went on to be the Major League Mental Skills Coach for the New York Mets. Lifrak, who has a Master's Degree in Exercise Science with a specialization in Sports Psychology from Ithaca College, lives in Sarasota, Florida.   Links: LinkedIn: https://www.linkedin.com/in/joshua-lifrak-59ab5442/   Facebook: https://www.facebook.com/jlifrak/   Instagram: https://www.instagram.com/joshualifrak/  And here's a link to an advance copy of the book:    https://app.box.com/s/qgi7q7093iaqmh0twvhlyx877y8xs9t9    Watch the full episode on YouTube: https://www.youtube.com/@richersoul Richer Soul Life Beyond Money. You got rich, now what? Let's talk about your journey to purposeful, intentional, amazing life. Where are you going to go and how are you going to get there? Let's figure that out together. At the core is the financial well being to be able to do what you want, when you want, how you want. It's about personal freedom! Thanks for listening! Show Sponsor: http://profitcomesfirst.com/ Schedule your free no obligation call: https://bookme.name/rockyl/lite/intro appointment 15 minutes If you like the show please leave a review on iTunes: http://bit.do/richersoul https://www.facebook.com/richersoul http://richersoul.com/ rocky@richersoul.com Some music provided by Junan from Junan Podcast Any financial advice is for educational purposes only and you should consult with an expert for your specific needs.

Sponsored by Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation. Intended for US Audiences. This information is for general purposes only and is not a substitute for consulting your healthcare provider about food allergy treatment. Dr. Ari Zelig has been financially compensated by Genentech and Novartis for his participation in this episode. Today, I'm joined by Dr. Ari Zelig, a board-certified allergist and immunologist to unpack what's really happening when it comes to food allergies - and why so many more people are dealing with them today. If you are navigating food allergies, or if you've ever wondered if what you're experiencing might be more than just a sensitivity, this episode features an informative discussion on these topics! In this episode, we dive into the reality of living with food allergies, from the day-to-day challenges that families carry to the misconceptions that still exist around what an allergic reaction to food actually looks like. Dr. Zelig breaks down IgE-mediated food allergies, what's happening in the body during a reaction, and why early exposure guidelines for kids have changed. Plus, we discuss a treatment option, XOLAIR (omalizumab), an FDA-approved prescription medication for subcutaneous use that can help reduce allergic reactions to multiple foods that may occur after accidental exposure in people with IgE-mediated food allergies one year of age and up. While taking XOLAIR you should continue to avoid all foods to which you are allergic. If you or a loved one has been diagnosed with food allergies, talk to your allergist and ask about XOLAIR. You can also find more information at XOLAIR.com. XOLAIR is one of several available treatment options for IgE-mediated food allergy and it may not be appropriate for all patients. What is XOLAIR?XOLAIR®(omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after accidentally eating one or more foods to which you are allergic. While taking XOLAIR you should continue to avoid all foods to which you are allergic. It is not known if XOLAIR is safe and effective in people with food allergy under 1 year of age. XOLAIR should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. What is the most important information I should know about XOLAIR?Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:· wheezing, shortness of breath, cough, chest tightness, or trouble breathing· low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”· flushing, itching, hives, or feeling warm· swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction. Please listen to the Important Safety Information throughout and stay tuned for additional safety information at the end of this podcast. See full Prescribing Information, including Medication Guide, at bit.ly/XOLPI. This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode. Produced by Dear Media M-US-00032583(v1.0) 5/26See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.